Functional and molecular imaging of localized and recurrent prostate cancer

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 40, Issue SUPPL. 1, 2013, Pages

  Grant, Kinzya ^a   Lindenberg, Maria L ^a   Shebel, Haytham ^b   Pang, Yuxi ^c   Agarwal, Harsh K ^d   Bernardo, Marcelino ^a,e   Kurdziel, Karen A ^a   Turkbey, Baris ^a   Choyke, Peter L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b MANSOURA UNIVERSITY   (Egypt)

^c PHILIPS HEALTHCARE   (United States)

^d PHILIPS RESEARCH LABORATORIES   (Netherlands)

^e SAIC FREDERICK INC   (United States)

Author keywords

MRI; PET CT; Prostate cancer

Indexed keywords

ACETIC ACID C 11; CHOLINE C 11; SODIUM FLUORIDE F 18;

ARTICLE; CANCER LOCALIZATION; CANCER RECURRENCE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIFFUSION WEIGHTED IMAGING; DYNAMIC CONTRAST ENHANCED NUCLEAR MAGNETIC RESONANCE IMAGING; HUMAN; INTERMETHOD COMPARISON; MALE; MOLECULAR IMAGING; MULTIPARAMETRIC NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; PROTON NUCLEAR MAGNETIC RESONANCE; T2 WEIGHTED NUCLEAR MAGNETIC RESONANCE IMAGING; AGED; DIFFERENTIAL DIAGNOSIS; METHODOLOGY; PATHOLOGY; PROSTATE TUMOR; REVIEW; SCINTISCANNING; TUMOR RECURRENCE; NEOPLASM RECURRENCE, LOCAL; PROCEDURES; PROSTATIC NEOPLASMS;

AGED; DIAGNOSIS, DIFFERENTIAL; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS;

EID: 84891596183     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-013-2419-6     Document Type: Article

References (74)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
3. Rørvik J, Halvorsen OJ, Espeland A, Haukaas S. Inability of refined CT to assess local extent of prostatic cancer. Acta Radiol. 1993;34:39-42.
4. Turkbey B, Bernardo M, Merino MJ, Wood BJ, Pinto PA, Choyke PL. MRI of localized prostate cancer: coming of age in the PSA era. Diagn Interv Radiol. 2012;18:34-45.
5. Bouchelouche K, Turkbey B, Choyke P, Capala J. Imaging prostate cancer: an update on positron emission tomography and magnetic resonance imaging. Curr Urol Rep. 2010;11:180-90.
6. Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G, et al. ESUR prostate MR guidelines 2012. Eur Radiol. 2012;22:746-57.
7. Tamada T, Sone T, Higashi H, Jo Y, Yamamoto A, Kanki A, et al. Prostate cancer detection in patients with total serumprostate-specific antigen levels of 4-10 ng/mL: diagnostic efficacy of diffusionweighted imaging, dynamic contrast-enhanced MRI, and T2- weighted imaging. AJR Am J Roentgenol. 2011;197:664-70.
8. Turkbey B, Pinto PA, Mani H, Bernardo M, Pang Y, McKinney YL, et al. Prostate cancer: value of multiparametric MR imaging at 3T for detection - histopathologic correlation. Radiology. 2010;255:89-99.
9. Vargas HA, Akin O, Shukla-Dave A, Zhang J, Zakian KL, Zheng J, et al. Performance characteristics of MR imaging in the evaluation of clinically low-risk prostate cancer: a prospective study. Radiology. 2012;265:478-87.
10. Akin O, Sala E, Moskowitz CS, Kuroiwa K, Ishill NM, Pucar D, et al. Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging. Radiology. 2006;239:784-92.
11. Vargas HA, Akin O, Franiel T, Goldman DA, Udo K, Touijer KA, et al. Normal central zone of the prostate and central zone involvement by prostate cancer: clinical and MR imaging implications. Radiology. 2012;262:894-902.
12. Hoeks CM, Hambrock T, Yakar D, Hulsbergen-van de Kaa CA, Feuth T, Witjes JA, et al. Transition zone prostate cancer: detection and localization with 3-T multiparametric MR imaging. Radiology. 2013;266:207-17.
13. Turkbey B, Choyke PL. Multiparametric MRI and prostate cancer diagnosis and risk stratification. Curr Opin Urol. 2012;22:310-5.
14. Bloch BN, Furman-Haran E, Helbich TH, Lenkinski RE, Degani H, Kratzik C, et al. Prostate cancer: accurate determination of extracapsular extension with high-spatial-resolution dynamic contrast-enhanced and T2-weighted MR imaging: initial results. Radiology. 2007;245:176-85.
15. Sala E, Akin O, Moskowitz CS, Eisenberg HF, Kuroiwa K, Ishill NM, et al. Endorectal MR imaging in the evaluation of seminal vesicle invasion: diagnostic accuracy and multivariate feature analysis. Radiology. 2006;238:929-37.
16. Vargas HA,Wassberg C, Akin O, Hricak H. MR imaging of treated prostate. Cancer Radiol. 2012;262:26-42.
17. Cirillo S, Petracchini M, Scotti L, Gallo T, Macera A, Bona MC, et al. Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2- weighted and contrast-enhanced imaging. Eur Radiol. 2009;19:761-9.
18. Casciani E, Polettini E, Carmenini E, Floriani I, Masselli G, Bertini L, et al. Endorectal and dynamic contrast-enhanced MRI for detection of local recurrence after radical prostatectomy. AJR Am J Roentgenol. 2008;190:1187-92.
19. Westphalen AC, Coakley FV, Roach 3rd M, McCulloch CE, Kurhanewicz J. Locally recurrent prostate cancer after external beam radiation therapy: diagnostic performance of 1.5-T endorectal MR imaging and MR spectroscopic imaging for detection. Radiology. 2010;256:485-92.
20. Padhani AR, Liu G, Koh DM, Chenevert TL, Thoeny HC, Takahara T, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia. 2009;11:102-25.
21. Zelhof B, Pickles M, Liney G, Gibbs P, Rodrigues G, Kraus S, et al. Correlation of diffusion-weighted magnetic resonance data with cellularity in prostate cancer. BJU Int. 2009;103:883-8.
22. Gibbs P, Tozer DJ, Liney GP, Turnbull LW. Comparison of quantitative T2 mapping and diffusion-weighted imaging in the normal and pathologic prostate. Magn Reson Med. 2001;46:1054-8.
23. Oto A, Kayhan A, Jiang Y, Tretiakova M, Yang C, Antic T, et al. Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging. Radiology. 2010;257:715-23.
24. Tamada T, Sone T, Toshimitsu S, Imai S, Jo Y, Yoshida K, et al. Age-related and zonal anatomical changes of apparent diffusion coefficient values in normal human prostatic tissues. J Magn Reson Imaging. 2008;27:552-6.
25. Wu LM, Xu JR, Ye YQ, Lu Q, Hu JN. The clinical value of diffusion-weighted imaging in combination with T2-weighted imaging in diagnosing prostate carcinoma: a systematic review and meta-analysis. AJR Am J Roentgenol. 2012;199:103-10.
26. Haider MA, van der Kwast TH, Tanguay J, Evans AJ, Hashmi AT, Lockwood G, et al. Combined T2-weighted and diffusionweighted MRI for localization of prostate cancer. AJR Am J Roentgenol. 2007;189:323-8.
27. Hambrock T, Somford DM, Huisman HJ, van Oort IM, Witjes JA, Hulsbergen-van de Kaa CA, et al. Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology. 2011;259:453-61.
28. Turkbey B, Shah VP, Pang Y, Bernardo M, Xu S, Kruecker J, et al. Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images? Radiology. 2011;258:488-95.
29. Kim CK, Park BK, Lee HM. Prediction of locally recurrent prostate cancer after radiation therapy: incremental value of 3T diffusion-weighted MRI. J Magn Reson Imaging. 2009;29:391-7.
30. Kim CK, Park BK, Lee HM, Kim SS, Kim E. MRI techniques for prediction of local tumor progression after high-intensity focused ultrasonic ablation of prostate cancer. AJR Am J Roentgenol. 2008;190:1180-6.
31. Metens T, Miranda D, Absil J, Matos C. What is the optimal bvalue in diffusion-weighted MR imaging to depict prostate cancer at 3T? Eur Radiol. 2012;22:703-9.
32. Mazaheri Y, Vargas HA, Akin O, Goldman DA, Hricak H. Reducing the influence of b-value selection on diffusionweighted imaging of the prostate: evaluation of a revised monoexponential model within a clinical setting. J Magn Reson Imaging. 2012;35:660-8.
33. Le Bihan D, Breton E, Lallemand D, Aubin ML, Vignaud J, Laval- Jeantet M. Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology. 1988;168:497-505.
34. Pang Y, Turkbey B, Bernardo M, Kruecker J, Kadoury S, Merino MJ, et al. Intravoxel incoherent motion MR imaging for prostate cancer: an evaluation of perfusion fraction and diffusion coefficient derived from different b-value combinations. Magn Reson Med. 2013;69:553-62.
35. Blackledge MD, Leach MO, Collins DJ, Koh DM. Computed diffusion-weighted MR imaging may improve tumor detection. Radiology. 2011;261:573-81.
36. Mazaheri Y, Shukla-Dave A, Hricak H, Fine SW, Zhang J, Inurrigarro G, et al. Prostate cancer: identification with combined diffusion-weighted MR imaging and 3D 1H MR spectroscopic imaging - correlation with pathologic findings. Radiology. 2008;246:480-8.
37. McLean MA, Barrett T, Gnanapragasam VJ, Priest AN, Joubert I, Lomas DJ, et al. Prostate cancer metabolite quantification relative to water in 1H-MRSI in vivo at 3 Tesla. Magn Reson Med. 2011;65:914-9.
38. Yakar D, Heijmink SW, Hulsbergen-van de Kaa CA, Huisman H, Barentsz JO, Futterer JJ, et al. Initial results of 3-dimensional 1Hmagnetic resonance spectroscopic imaging in the localization of prostate cancer at 3 Tesla: should we use an endorectal coil? Invest Radiol. 2011;46:301-306.
39. Yerram NK, Volkin D, Turkbey B, Nix J, Hoang AN, Vourganti S, et al. Low suspicion lesions on multiparametric magnetic resonance imaging predict for the absence of high-risk prostate cancer. BJU Int. 2012;110(11 Pt B):E783-8.
40. Coakley FV, Kurhanewicz J, Lu Y, Jones KD, Swanson MG, Chang SD, et al. Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging. Radiology. 2002;223:91-7.
41. Futterer JJ, Heijmink SW, Scheenen TW, Veltman J, Huisman HJ, Vos P, et al. Prostate cancer localization with dynamic contrastenhanced MR imaging and proton MR spectroscopic imaging. Radiology. 2006;241:449-58.
42. Turkbey B, Mani H, Shah V, Rastinehad AR, Bernardo M, Pohida T, et al. Multiparametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds. J Urol. 2011;186:1818-24.
43. Yu KK, Scheidler J, Hricak H, Vigneron DB, Zaloudek CJ, Males RG, et al. Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology. 1999;213:481-8.
44. Zakian KL, Sircar K, Hricak H, Chen HN, Shukla-Dave A, Eberhardt S, et al. Correlation of proton MR spectroscopic imaging with Gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology. 2005;234(3):804-14.
45. Kobus T, Hambrock T, Hulsbergen-van de Kaa CA, Wright AJ, Barentsz JO, Heerschap A, et al. In vivo assessment of prostate cancer aggressiveness using magnetic resonance spectroscopic imaging at 3T with an endorectal coil. Eur Urol. 2011;60:1074-80.
46. Shukla-Dave A, Hricak H, Akin O, Yu C, Zakian KL, Udo K, et al. Preoperative nomograms incorporating magnetic resonance imaging and spectroscopy for prediction of insignificant prostate cancer. BJU Int. 2012;109:1315-22.
47. Westphalen AC, Reed GD, Vinh PP, Sotto C, Vigneron DB, Kurhanewicz J. Multiparametric 3T endorectal MRI after external beam radiation therapy for prostate cancer. J Magn Reson Imaging. 2012;36:430-7.
48. Pucar D, Shukla-Dave A, Hricak H, Moskowitz CS, Kuroiwa K, Olgac S, et al. Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy - initial experience. Radiology. 2005;236:545-53.
49. Zakian KL, Hricak H, Ishill N, Reuter VE, Eberhardt S, Moskowitz CS, et al. An exploratory study of endorectal magnetic resonance imaging and spectroscopy of the prostate as preoperative predictive biomarkers of biochemical relapse after radical prostatectomy. J Urol. 2010;184:2320-7.
50. Sciarra A, Panebianco V, Salciccia S, Lisi D, Alfarone A, Gentilucci A, et al. Determination of the time for maximal response to neoadjuvant hormone therapy for prostate cancer using magnetic resonance with spectroscopy (MRSI) and dynamic contrast enhancement (DCEMR). Urol Oncol. 2012;30:614-9.
51. Verma S, Turkbey B, Muradyan N, Rajesh A, Cornud F, Haider MA, et al. Overview of dynamic contrast-enhanced MRI in prostate cancer diagnosis and management. AJR Am J Roentgenol. 2012;198:1277-88.
52. Haider MA, Chung P, Sweet J, Toi A, Jhaveri K, Ménard C, et al. Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int J Radiat Oncol Biol Phys. 2008;70:425-30.
53. Puech P, Betrouni N, Makni N, Dewalle AS, Villers A, Lemaitre L. Computer-assisted diagnosis of prostate cancer using DCE-MRI data: design, implementation and preliminary results. Int J Comput Assist Radiol Surg. 2009;4:1-10.
54. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, et al. Estimating kinetic parameters from dynamic contrastenhanced T1-weighted MRI of a diffusible tracer: standardized quantities and symbols. J Magn Reson Imaging. 1999;10:223-32.
55. Ocak I, Bernardo M, Metzger G, Barrett T, Pinto P, Albert PS, et al. Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters. AJR Am J Roentgenol. 2007;189:849.
56. Delongchamps NB, Rouanne M, Flam T, Beuvon F, Liberatore M, Zerbib M, et al. Multiparametric magnetic resonance imaging for the detection and localization of prostate cancer: combination of T2-weighted, dynamic contrast enhanced and diffusion-weighted imaging. BJU Int. 2011;107:1411-8.
57. Sella T, Schwartz LH, Swindle PW, Onyebuchi CN, Scardino PT, Scher HI, et al. Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology. 2004;231:379-85.
58. 18F-FDG-PET/CT. Ann Nucl Med. 2012;26:138-45.
59. Minamimoto R, Uemura H, Sano F, Terao H, Nagashima Y, Yamanaka S, et al. The potential of FDG-PET/CT for detecting prostate cancer in patients with an elevated serum PSA level. Ann Nucl Med. 2011;25:21-7.
60. Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med. 1998;39:990-5.
61. Farsad M, Schiavina R, Castellucci P, Nanni C, Corti B, Martorana G, et al. Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis. J Nucl Med. 2005;46:1642-9.
62. 11C-choline-PET/CT and whole body-MRI for staging of prostate cancer. Nuklearmedizin. 2007;46:161-8.
63. 11C-choline PET and MR imaging combined with proton MR spectroscopy. Eur J Nucl Med Mol Imaging. 2005;32:742-8.
64. Beer AJ, Eiber M, Souvatzoglou M, Holzapfel K, Ganter C, Weirich G, et al. Restricted water diffusibility as measured by diffusion-weighted MR imaging and choline uptake in (11)C-choline PET/CT are correlated in pelvic lymph nodes in patients with prostate cancer. Mol Imaging Biol. 2011;13:352-61.
65. Park H, Wood D, Hussain H, Meyer CR, Shah RB, Johnson TD, et al. Introducing parametric fusion PET/MRI of primary prostate cancer. J Nucl Med. 2012;53:546-51.
66. Kato T, Tsukamoto E, Kuge Y, Takei T, Shiga T, Shinohara N, et al. Accumulation of [11C]acetate in normal prostate and benign prostatic hyperplasia: comparison with prostate cancer. Eur J Nucl Med Mol Imaging. 2002;29:1492-5.
67. 11C-Acetate PET/CT in localized prostate cancer: a study with MRI and histopathologic correlation. J Nucl Med. 2012;53:538-45.
68. 11C-acetate PET/CT. Eur J Radiol. 2012;81:2966-72.
69. 11C-acetate PET/CT and 1H-MR spectroscopy. J Nucl Med. 2010;51:1676-83.
70. 11C-acetate positron emission tomography imaging and image fusion with computed tomography and magnetic resonance imaging in patients with recurrent prostate cancer. J Clin Oncol. 2006;24:2513-9.
71. Schuster DM, Votaw JR, Nieh PT, Yu W, Nye JA, Master V, et al. Initial experience with the radiotracer anti-1-amino-3-18Ffluorocyclobutane- 1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med. 2007;48:56-63.
72. 18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT. Radiology. 2011;259:852-61.
73. Mosavi F, Johansson S, Sandberg DT, Turesson I, Sörensen J, Ahlström H. Whole-body diffusion-weighted MRI compared with (18)F-NaF PET/CT for detection of bone metastases in patients with high-risk prostate carcinoma. AJR Am J Roentgenol. 2012;199:1114-20.
74. Kurdziel KA, Shih JH, Apolo AB, Lindenberg L, Mena E, McKinney YY, et al. The kinetics and reproducibility of 18Fsodium fluoride for oncology using current PET camera technology. J Nucl Med. 2012;53:1175-84.